ERBB2 and breast carcinoma: Therefore, drugs that inhibit the kinases in this pathway are used in HER2+ breast cancers in combination with HER2 targeted therapies that rely on trastuzumab and Lapatinib (Lin et al., 2013; Manning and Toker, 2017; Fujimoto et al., 2020; Martorana et al., 2021).